Literature DB >> 8080747

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.

W Graf1, L Påhlman, R Bergström, B Glimelius.   

Abstract

This analysis was conducted to evaluate the independent relationship between survival and response to chemotherapy in advanced colorectal cancer. In order to correct for the guarantee time effect, patients dying before the response evaluation were excluded from the analyses. A previously constructed prognostic model containing 11 variables was applied to 324 patients. When the response categories were analysed together with the prognostic variables, it was found that a response was associated with a definite survival advantage (P < 0.001), whereas the influence of all the other variables decreased. The corrected survival advantage (relative progressive disease) was 11 months after a complete response, 6 months after a partial response and 4 months after stable disease. The survival advantage was of a similar magnitude when the analyses were repeated in an independent population comprising 198 patients in whom the prognostic model was extended to include also a set of laboratory values. The results show that a response to chemotherapy is associated with a longer survival also after correction for the guarantee time effect and the distribution of prognostic variables.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080747      PMCID: PMC2033339          DOI: 10.1038/bjc.1994.345

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Clinical management of advanced gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

2.  Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report.

Authors:  P Lavin; A Mittelman; H Douglass; P Engstrom; D Klaassen
Journal:  Cancer       Date:  1980-10-01       Impact factor: 6.860

3.  Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens.

Authors:  B Glimelius; K Hoffman; M Olafsdottir; L Påhlman; P O Sjödén; A Wennberg
Journal:  Eur J Cancer Clin Oncol       Date:  1989-05

4.  Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer.

Authors:  G Carlsson; W Graf; B G Gustavsson; B Glimelius; L Påhlman; P C Spears
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

6.  Response to treatment and its influence on survival in metastatic breast cancer.

Authors:  A H Paterson; M Cyr; O Szafran; A W Lees; J Hanson
Journal:  Am J Clin Oncol       Date:  1985-08       Impact factor: 2.339

7.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

8.  Sequential methotrexate--5-FU--leucovorin (MFL) in advanced colorectal cancer.

Authors:  B Glimelius; C Ginman; S Graffman; L Påhlman; E Ståhle
Journal:  Eur J Cancer Clin Oncol       Date:  1986-03

9.  Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

Authors:  R P A'Hern; S R Ebbs; M B Baum
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  Assessment of response to therapy in advanced breast cancer.

Authors:  J L Hayward; P P Carbone; J C Heusen; S Kumaoka; A Segaloff; R D Rubens
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more
  8 in total

1.  A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers.

Authors:  Seok-Won Hyung; Min Young Lee; Jong-Han Yu; Byunghee Shin; Hee-Jung Jung; Jong-Moon Park; Wonshik Han; Kyung-Min Lee; Hyeong-Gon Moon; Hui Zhang; Ruedi Aebersold; Daehee Hwang; Sang-Won Lee; Myeong-Hee Yu; Dong-Young Noh
Journal:  Mol Cell Proteomics       Date:  2011-07-28       Impact factor: 5.911

2.  Predicting the toxicity of weekly docetaxel in advanced cancer.

Authors:  Kellie A Charles; Laurent P Rivory; Martin R Stockler; Philip Beale; Jane Beith; Michael Boyer; Stephen J Clarke
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.

Authors:  Chikako Suzuki; Lennart Blomqvist; Thomas Hatschek; Lena Carlsson; Zakaria Einbeigi; Barbro Linderholm; Birgitta Lindh; Niklas Loman; Martin Malmberg; Samuel Rotstein; Martin Söderberg; Marie Sundqvist; Thomas M Walz; Gunnar Aström; Hirofumi Fujii; Hans Jacobsson; Bengt Glimelius
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

Review 4.  Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.

Authors:  Hiroshi Imaoka; Mitsuhito Sasaki; Hideaki Takahashi; Yusuke Hashimoto; Izumi Ohno; Shuichi Mitsunaga; Kazuo Watanabe; Kumiko Umemoto; Gen Kimura; Yuko Suzuki; Motoyasu Kan; Masafumi Ikeda
Journal:  Oncologist       Date:  2018-08-02

5.  Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

Authors:  John R Goffin; Greg R Pond
Journal:  BMC Med Res Methodol       Date:  2011-12-12       Impact factor: 4.615

6.  A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.

Authors:  J K Joffe; T J Perren; C Bradley; J Primrose; S Hallam; U Ward; J M Illingworth; P J Selby
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.

Authors:  M A Bensmaïne; M Marty; A de Gramont; S Brienza; F Lévi; M Ducreux; E François; E Gamelin; H Bleiberg; E Cvitkovic
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

8.  Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

Authors:  M J Mackean; J Cassidy; D I Jodrell; J Paul; N S Reed; P A Canney; H Yosef; T Habeshaw; A G Robertson; A McInnes; C J Twelves
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.